- Home
- RA vs CSTL Comparison
RA vs CSTL Comparison
Compare RA & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RA
- CSTL
- Stock Information
- Founded
- RA 2016
- CSTL 2007
- Country
- RA United States
- CSTL United States
- Employees
- RA 1260
- CSTL N/A
- Industry
- RA Investment Managers
- CSTL Medical Specialities
- Sector
- RA Finance
- CSTL Health Care
- Exchange
- RA Nasdaq
- CSTL Nasdaq
- Market Cap
- RA 711.7M
- CSTL 661.7M
- IPO Year
- RA N/A
- CSTL 2019
- Fundamental
- Price
- RA $13.13
- CSTL $31.63
- Analyst Decision
- RA
- CSTL Strong Buy
- Analyst Count
- RA 0
- CSTL 6
- Target Price
- RA N/A
- CSTL $38.33
- AVG Volume (30 Days)
- RA 280.8K
- CSTL 349.1K
- Earning Date
- RA 01-01-0001
- CSTL 11-03-2025
- Dividend Yield
- RA 14.73%
- CSTL N/A
- EPS Growth
- RA N/A
- CSTL N/A
- EPS
- RA N/A
- CSTL N/A
- Revenue
- RA N/A
- CSTL $343,530,000.00
- Revenue This Year
- RA N/A
- CSTL N/A
- Revenue Next Year
- RA N/A
- CSTL N/A
- P/E Ratio
- RA N/A
- CSTL N/A
- Revenue Growth
- RA N/A
- CSTL 10.15
- 52 Week Low
- RA $11.89
- CSTL $14.59
- 52 Week High
- RA $17.32
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- RA 40.86
- CSTL 82.58
- Support Level
- RA $13.11
- CSTL $23.31
- Resistance Level
- RA $13.23
- CSTL $24.64
- Average True Range (ATR)
- RA 0.12
- CSTL 1.31
- MACD
- RA -0.00
- CSTL 0.61
- Stochastic Oscillator
- RA 37.97
- CSTL 97.84
About RA Brookfield Real Assets Income Fund Inc.
Brookfield Real Assets Income Fund Inc. is a diversified, closed-end management investment company. Its investment objective is to seek a high total return, through high current income and secondarily, through the growth of capital. The Fund seeks to achieve its investment objective by investing in the real asset class, which includes the following: Real Estate Securities; Infrastructure Securities; and Natural Resources Securities. The Firm manages separate accounts, registered funds, and opportunistic strategies for institutional and individual clients, including financial institutions, public and private pension plans, insurance companies, endowments and foundations, sovereign wealth funds, and high-net-worth investors.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.